Circio announces completion of planned safety review and opening for full enrollment of TG01 study at Oslo University Hospital
· Seven patients were enrolled in the safety cohort with follow-up for three months · TG01 was well tolerated, and no safety concerns were reported · The study is now open for full enrollmentOslo, Norway, 7 December 2023 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA and immunotherapy medicines, today announces that mutant RAS cancer vaccine TG01 adjuvanted by QS-21 STIMULON has passed the planned safety cohort review without any concerns in the multiple myeloma trial at Oslo University Hospital (OUS). The study has now opened for full